START FREE TRIAL
Home Healthcare AbbVie Inc

AbbVie Inc

$19.00

SKU: ABBV Category:

Description

AbbVie Raises 2026 Revenue Guidance to $67.8 Billion: Can Skyrizi and Rinvoq Sustain Growth?

 

AbbVie Inc. reported third-quarter 2026 results characterized by revenue and earnings growth that exceeded internal guidance. Adjusted earnings per share were $3.82, surpassing the midpoint of guidance by $0.07, while total net revenues reached $17.4 billion, $200 million above expectations and reflecting operational growth of 10.5%. Key products including Skyrizi, Rinvoq, Vraylar, Ubrelvy, Qulipta, and Venclexta demonstrated strong double-digit growth, prompting the company to raise its full-year revenue guidance by $200 million to approximately $67.8 billion. The company also increased its quarterly cash dividend by 5.2%, continuing a long-term history of dividend growth. Within immunology, revenues approached $9.2 billion, driven primarily by Skyrizi and Rinvoq, which exceeded expectations with operational growth of 22.9% and 24.3%, respectively. Skyrizi maintained robust market share in psoriasis, unaffected by emerging oral competitors, and showed promising uptake in inflammatory bowel disease (IBD) with recent U.S. approval of a subcutaneous induction dosing option for Crohn’s disease.